People living with pain and healthcare professionals are asked to
design the ideal exam room experience to foster communication during
Pain Awareness Month this September
FRAZER, Pa.--(BUSINESS WIRE)--Sep. 8, 2015--
Teva Pharmaceutical Industries Ltd. today announced the launch of Design
for Dialogue, a program featured on PainMatters.com, that seeks to
reduce challenges to open dialogue around responsible pain management.
Kicking off at the PAINWeek National Conference during Pain Awareness
Month, Teva is asking individuals living with pain and healthcare
professionals who treat pain to visit PainMatters.com to design the
ideal exam room experience that would help foster conversations about
the impact of pain, the risk of prescription drug abuse and the role of
abuse deterrence technology.
In a survey conducted by Teva in collaboration with the American Academy
of Pain Management and the U.S. Pain Foundation, healthcare
professionals and people affected by pain recognized their personal
responsibility in helping address prescription drug abuse, but
acknowledged conversations about the issue can be uncomfortable. Other
research shows that simple changes to the exam room environment can
affect people’s mood and behavior. Design for Dialogue invites the pain
community to reimagine the exam room experience and implement simple
changes to the physical healthcare environment that can help address
this discomfort.
“Effective communication is essential to achieving positive patient
outcomes and experiences, and it provides the basis for establishing
strong provider-patient relationships,” said Laura Cooley, Ph.D.,
director of education and outreach, American Academy on Communication in
Healthcare. “Design for Dialogue sheds light on how the exam room
environment, from the aesthetics to provider–patient interaction, can
hinder communications, and offers practical resources to help foster a
more open dialogue.”
By visiting PainMatters.com, people living with and treating pain can
let their voices be heard and inspire change by designing their ideal
exam room experience. Participants have the options to choose wall
color, lighting, furniture and flooring, as well as the communication
resources available in the exam room that they believe would help foster
dialogue. Feedback from the pain community will be collected until
December 31, 2015, and the ideal exam room experience will be revealed
in early 2016.
“We understand the need for innovative solutions to address some of the
complex challenges facing pain care today, including the impact of pain
and the risks of prescription drug abuse,” said John Hassler, Vice
President and General Manager, Teva CNS. “Design for Dialogue is another
example of our commitment to the pain community to bring practical
information and resources to healthcare professionals and people with
pain to help advance responsible pain management.”
Visit PainMatters.com
to design an ideal exam room and access tools and information to help
guide discussions that help foster pain management.
About Pain Matters
Pain Matters was developed by Teva Pharmaceuticals to offer practical
information and resources for healthcare professionals and people
affected by chronic pain as they navigate the evolving and complex pain
care landscape. PainMatters.com
provides healthcare professionals information and resources on
responsible pain management. It also provides information on stakeholder
efforts in abuse deterrence, including abuse-deterrence technologies –
featuring a video on the science behind these technologies.
About Teva
Teva Pharmaceutical Industries Ltd is a leading global pharmaceutical
company that delivers high-quality, patient-centric healthcare solutions
to millions of patients every day. In addition to being the world’s
largest generic medicines producer, Teva has world-leading positions in
multiple specialty medicines therapeutic areas. In North America, Teva’s
Specialty Medicines business focuses on innovative treatments for
disorders of the central nervous system (CNS), including pain, and
respiratory diseases, as well as having a strong presence in oncology,
women’s health and select, US-only brands. Our focus is on creating new
ways of addressing unmet patient needs, by combining drug development
capabilities with devices, patient services and technologies. For more
information, visit www.tevausa.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150908005343/en/
Source: Teva Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd.
United States
Nancy Leone,
215-284-0213
or
Michelle Larkin, 610-786-7335
or
Doris
Saltkill, 913-777-3343